Compare AMKR & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMKR | BMRN |
|---|---|---|
| Founded | 1968 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6B | 13.0B |
| IPO Year | 1997 | 1999 |
| Metric | AMKR | BMRN |
|---|---|---|
| Price | $47.76 | $66.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 18 |
| Target Price | $64.50 | ★ $88.22 |
| AVG Volume (30 Days) | ★ 3.8M | 2.2M |
| Earning Date | 04-27-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.47% | N/A |
| EPS Growth | ★ 4.90 | N/A |
| EPS | 0.33 | ★ 0.77 |
| Revenue | ★ $4,052,650,000.00 | $1,313,646,000.00 |
| Revenue This Year | $13.24 | $15.02 |
| Revenue Next Year | $9.90 | $12.23 |
| P/E Ratio | $142.55 | ★ $86.55 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $25.52 | $49.26 |
| 52 Week High | $96.68 | $70.98 |
| Indicator | AMKR | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 39.35 | 56.83 |
| Support Level | $45.94 | $58.03 |
| Resistance Level | $47.28 | $70.98 |
| Average True Range (ATR) | 2.46 | 1.56 |
| MACD | -0.01 | -0.34 |
| Stochastic Oscillator | 10.28 | 46.31 |
Amkor Technology Inc is a OSAT (outsourced semiconductor assembly and test) service provider. It has pioneered the outsourcing of integrated circuit (IC) packaging and test services and is a strategic manufacturing partner for the semiconductor companies, foundries, and electronics original equipment manufacturers (OEMs). The firm's products are organized into two categories namely advanced products that include flip chip, fine pitch bumping, wafer-level processing, advanced SiPs, power modules, and others, and Mainstream products that includes wirebond packaging and testing. The company derives maximum revenue from the advanced products category. The company derives majority of its revenue from Foreign states.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.